Connect your AI

Organon OGN Change in Other Current Assets

Change in Other Current Assets at other companies

West Pharmaceutical ServicesWST

-$2.43M-267%

Other financials

Income statement

Revenue$1.5B-3.5%

Gross profit$783.0M-6.9%

Net income$146.0M+67.8%

EPS (diluted)$0.55+66.7%

Balance sheet

Cash & equivalents$1.1B+104%

Total debt$8.6B-4.3%

Total equity$903.0M+66.6%

Total assets$13.0B-1.2%

Cash flow

Operating cash flow$225.0M+200%

CapEx$37.0M+15.6%

Free cash flow$188.0M+337%

Valuation

Market cap$3.53B-59.4%

Profitability

Gross margin52.8%-4.4pp

Net margin8%-12.3pp

FCF margin11.1%-1.3pp

Returns & leverage

Return on equity71.6%—

Debt / equity9.5×-7.0×

Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherCurrentAssets.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's change in other current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Organon's change in other current assets?: Organon (OGN) reported change in other current assets of $15M in Q1 2026.
How has Organon's change in other current assets changed year-over-year?: Organon's change in other current assets increased by 36.4% year-over-year, from $11M to $15M.
What does change in other current assets mean?: Change in miscellaneous current assets not classified in specific working capital categories.